Novo Nordisk's Q2 profit beats forecasts, raises outlook
NVO•Q2 profit beats forecasts and outlook rises
COPENHAGEN, Aug. 4 (Reuters) - Novo Nordisk NOVOb.CO, the maker of weight-loss drug Wegovy, reported a second-quarter adjusted operating profit above forecasts on Tuesday and raised its full-year profit and sales outlook.
The Danish drugmaker is battling to claw back lost ground on Eli Lilly LLY.N in the lucrative obesity drug market, as investors look for signs its turnaround can last and its new Wegovy pill can support longer-term growth.
